MD995Z - Метод лечения инфекции вызываемой вирусом Herpes simplex 1 и 2 типов - Google Patents
Метод лечения инфекции вызываемой вирусом Herpes simplex 1 и 2 типов Download PDFInfo
- Publication number
- MD995Z MD995Z MDS20150006A MDS20150006A MD995Z MD 995 Z MD995 Z MD 995Z MD S20150006 A MDS20150006 A MD S20150006A MD S20150006 A MDS20150006 A MD S20150006A MD 995 Z MD995 Z MD 995Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- acyclovir
- infection
- herpes
- hsv1
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 28
- 241000700588 Human alphaherpesvirus 1 Species 0.000 title description 60
- 241000701074 Human alphaherpesvirus 2 Species 0.000 title description 2
- 238000011282 treatment Methods 0.000 claims abstract description 91
- 229960004150 aciclovir Drugs 0.000 claims abstract description 76
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 74
- 238000012360 testing method Methods 0.000 claims abstract description 17
- 241000700605 Viruses Species 0.000 claims abstract description 14
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 14
- 208000009889 Herpes Simplex Diseases 0.000 claims abstract description 10
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 6
- 239000000932 sedative agent Substances 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 230000035945 sensitivity Effects 0.000 claims abstract description 5
- 230000000202 analgesic effect Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims abstract description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims abstract description 3
- 230000001624 sedative effect Effects 0.000 claims abstract description 3
- 230000000977 initiatory effect Effects 0.000 claims description 12
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 7
- 108020004440 Thymidine kinase Proteins 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 206010019973 Herpes virus infection Diseases 0.000 description 41
- 241001529453 unidentified herpesvirus Species 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000009467 reduction Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 10
- 108010078049 Interferon alpha-2 Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 241000700584 Simplexvirus Species 0.000 description 7
- 230000007969 cellular immunity Effects 0.000 description 7
- 238000003759 clinical diagnosis Methods 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000012332 laboratory investigation Methods 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- ZABSXKJOMUONGB-UHFFFAOYSA-N 2-oxo-2-(9-oxofluoren-2-yl)acetaldehyde Chemical compound C1=CC=C2C(=O)C3=CC(C(=O)C=O)=CC=C3C2=C1 ZABSXKJOMUONGB-UHFFFAOYSA-N 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 230000003622 anti-hsv Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000003771 laboratory diagnosis Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- OCOSYMCDPNAWPA-UHFFFAOYSA-N 2,4-dibromo-6-(3,5-dibromo-2,4-dihydroxyphenyl)benzene-1,3-diol Chemical compound OC1=C(Br)C(O)=C(Br)C=C1C1=CC(Br)=C(O)C(Br)=C1O OCOSYMCDPNAWPA-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010013082 Discomfort Diseases 0.000 description 4
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- HZVGIXIRNANSHU-UHFFFAOYSA-N naphthalene-1,2,3,4-tetrone Chemical compound C1=CC=C2C(=O)C(=O)C(=O)C(=O)C2=C1 HZVGIXIRNANSHU-UHFFFAOYSA-N 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 238000002636 symptomatic treatment Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010042566 Superinfection Diseases 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 description 1
- SGHTWHQDAWEBOD-YYWUANBLSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;2-acetyloxybenzoic acid;n-(4-ethoxyphenyl)acetamide;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione;phosphoric acid;1,3,7-trimethylpurine-2,6-dio Chemical compound OP(O)(O)=O.CCOC1=CC=C(NC(C)=O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC SGHTWHQDAWEBOD-YYWUANBLSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000751100 Pityopus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- AYWLSIKEOSXJLA-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 AYWLSIKEOSXJLA-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 244000240602 cacao Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- UOMKBIIXHQIERR-UHFFFAOYSA-N cridanimod Chemical compound C1=CC=C2N(CC(=O)O)C3=CC=CC=C3C(=O)C2=C1 UOMKBIIXHQIERR-UHFFFAOYSA-N 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N hydroxycarbonylphosphonic acid Natural products OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- ZRFIFDFEDPJBII-UHFFFAOYSA-N methyl 2-[4-(2-piperidin-1-ylethoxy)benzoyl]benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1C(=O)C(C=C1)=CC=C1OCCN1CCCCC1 ZRFIFDFEDPJBII-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 231100000873 signs of neurotoxicity Toxicity 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- BSVYJQAWONIOOU-UHFFFAOYSA-N tilorone dihydrochloride Chemical compound Cl.Cl.C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 BSVYJQAWONIOOU-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение относится к медицине, в частности к методу лечения инфекции вызванной вирусом Herpes simplex 1 и 2 типов.Согласно изобретению, метод состоит в осуществлении клинического и параклинического обследования пациента и инициировании этиотропного лечения ацикловиром, а также противовоспалительного, седативного, анальгезирующего, местного, иммуномодуляторного и витаминотерапевтического лечения, при этом в течение 12…24 часов после клинического обследования осуществляют тест на чувствительность к ацикловиру штаммов вируса, взятых из герпетических везикул, и в случае обнаружения резистентных штаммов к ацикловиру, его заменяют со второго дня лечения на противовирусный препарат с тимидинкиназа-независимым действием на основе интерферона человеческого рекомбинантного α-2b.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150006A MD995Z (ru) | 2015-01-27 | 2015-01-27 | Метод лечения инфекции вызываемой вирусом Herpes simplex 1 и 2 типов |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20150006A MD995Z (ru) | 2015-01-27 | 2015-01-27 | Метод лечения инфекции вызываемой вирусом Herpes simplex 1 и 2 типов |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD995Y MD995Y (ru) | 2016-01-31 |
| MD995Z true MD995Z (ru) | 2016-08-31 |
Family
ID=55235465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20150006A MD995Z (ru) | 2015-01-27 | 2015-01-27 | Метод лечения инфекции вызываемой вирусом Herpes simplex 1 и 2 типов |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD995Z (ru) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU491387A1 (ru) * | 1974-07-18 | 1975-11-15 | Всесоюзный Научно-Исследовательский Институт Лекарственных Растений | Флавоноидные соединени , про вл ющие противогерпетическую активность |
| SU1246005A1 (ru) * | 1984-07-13 | 1986-07-23 | Московский научно-исследовательский институт вирусных препаратов | Способ оценки фармакологической активности химиопрепаратов дл лечени генитального герпеса |
| SU1530189A1 (ru) * | 1988-04-15 | 1989-12-23 | Научно-Исследовательский Институт Эпидемиологии И Микробиологии Им.Почетного Акад.Н.Ф.Гамалеи | Способ лечени простого рецидивирующего герпеса |
| SU1720649A1 (ru) * | 1981-08-06 | 1992-03-23 | Институт Биоорганической Химии Ан Узсср | "Антигерпетическое средство "мегосин" |
| MD1051C2 (ru) * | 1996-12-02 | 1999-05-31 | Centrul National Stiintifico-Practic De Igiena Si Epidemiologie Al Ministerului Sanatatii Din Republica Moldova | Антигерпетическое средство |
| MD1473F2 (en) * | 1998-06-02 | 2000-05-31 | Centrul National Stiintifico P | Antiherpetic remedy |
| RU2492861C1 (ru) * | 2012-05-29 | 2013-09-20 | Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") | Способ лечения рецидивирующего урогенитального герпеса с симптомами хронической усталости |
-
2015
- 2015-01-27 MD MDS20150006A patent/MD995Z/ru not_active IP Right Cessation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU491387A1 (ru) * | 1974-07-18 | 1975-11-15 | Всесоюзный Научно-Исследовательский Институт Лекарственных Растений | Флавоноидные соединени , про вл ющие противогерпетическую активность |
| SU1720649A1 (ru) * | 1981-08-06 | 1992-03-23 | Институт Биоорганической Химии Ан Узсср | "Антигерпетическое средство "мегосин" |
| SU1246005A1 (ru) * | 1984-07-13 | 1986-07-23 | Московский научно-исследовательский институт вирусных препаратов | Способ оценки фармакологической активности химиопрепаратов дл лечени генитального герпеса |
| SU1530189A1 (ru) * | 1988-04-15 | 1989-12-23 | Научно-Исследовательский Институт Эпидемиологии И Микробиологии Им.Почетного Акад.Н.Ф.Гамалеи | Способ лечени простого рецидивирующего герпеса |
| MD1051C2 (ru) * | 1996-12-02 | 1999-05-31 | Centrul National Stiintifico-Practic De Igiena Si Epidemiologie Al Ministerului Sanatatii Din Republica Moldova | Антигерпетическое средство |
| MD1473F2 (en) * | 1998-06-02 | 2000-05-31 | Centrul National Stiintifico P | Antiherpetic remedy |
| RU2492861C1 (ru) * | 2012-05-29 | 2013-09-20 | Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") | Способ лечения рецидивирующего урогенитального герпеса с симптомами хронической усталости |
Non-Patent Citations (2)
| Title |
|---|
| Герпесвирусная инфекция. Под редакцией В.П. Малого. Москва, Медицинская практика, 2009, p. 36-57 * |
| Исаков В.А., Архипова Е.И., Исаков Д.В. Герпесвирусные инфекции человека (руководство для врачей). Санкт-Петербург, 2006, p. 276-282 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD995Y (ru) | 2016-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LAWRENCE et al. | Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention | |
| Whitley et al. | Clinical management of herpes simplex virus infections: past, present, and future | |
| Blough et al. | Successful treatment of human genital herpes infections with 2-deoxy-D-glucose | |
| Azher et al. | Herpes simplex keratitis: challenges in diagnosis and clinical management | |
| Piperi et al. | Management of oral herpes simplex virus infections: The problem of resistance. A narrative review | |
| Whitley et al. | Pathogenesis and disease | |
| Dworkin et al. | Recommendations for the management of herpes zoster | |
| Chou et al. | Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications | |
| Yeung-Yue et al. | Herpes simplex viruses 1 and 2 | |
| Fontenelle et al. | Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats | |
| Miller et al. | Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment | |
| Mustafa et al. | Herpes simplex virus infections, Pathophysiology and Management | |
| Thurman et al. | Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention | |
| Desai et al. | A rare case of varicella-zoster virus reactivation following recovery from COVID-19 | |
| US20220088403A1 (en) | Methods And Compositions For Treating Coronavirus | |
| Ivanov et al. | Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review | |
| Stoopler et al. | Update on herpesvirus infections | |
| Mehrmal et al. | Diagnostic methods and management strategies of herpes simplex and herpes zóster infections | |
| Goodman et al. | Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis | |
| Lewin et al. | Surveillance for feline herpesvirus type 1 mutation and development of resistance in cats treated with antiviral medications | |
| Spertus et al. | Effects of orally administered raltegravir in cats with experimentally induced ocular and respiratory feline herpesvirus-1 infection | |
| Diaz-Mitoma et al. | Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes | |
| Ikematsu et al. | Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013–2014 Japanese season | |
| Stiles et al. | Effects of λ-carrageenan on in vitro replication of feline herpesvirus and on experimentally induced herpetic conjunctivitis in cats | |
| Koh et al. | Zosteriform herpes simplex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| MK4Y | Short term patent expired |